Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.03.669 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jerry A Nick und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Jewish Health, Denver, CO 80206, USA; Department of Medicine, University of Colorado School of Medicine, Aurora, CO …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Phage Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Bacteriophages (phages) are viruses that selectively infect bacteria and have been utilized to treat Mycobacterium abscessus (Mab) with varying success. The POSTSTAMP study is an ongoing, multi-site phage therapy protocol for treatment-refractory pulmonary Mab disease in people with cystic fibrosis (pwCF). Participants (n = 10) are prospectively assessed while utilizing FDA investigational new drug (IND) approval for compassionate use. Participants are >6 years old, able to produce sputum, have been treated with guideline-based antibiotic therapy (GBT) for >12 months without culture conversion, and are currently receiving GBT with at least 3 and ≥ 80 % positive Mab cultures in the prior year. At enrollment, an isolate is assessed for the availability of lytic phage(s). Open-label phage therapy consists of 1 or 2 phages administered intravenously twice daily for 52 weeks. Participants without a phage match will be followed on GBT as a comparison group. Follow-up visits will occur monthly, with one follow-up visit at completion and intermittent visits for a year after phage therapy. Efficacy will be assessed by culture, standard clinical measures and a patient-reported quality-of-life instrument. Frequency of Mab detection 12 months prior to treatment will be compared with the 12-month period beginning 6 months after treatment initiation. Individual-level tests of difference in percent positive cultures within subjects will be used to identify "responders". Collectively and including all persons, a mixed-effect model will be used to test for a difference in frequency of Mab detection following treatment or without treatment. The trial will also test for markers of treatment failure and pathogen adaptation in participants who did not achieve microbiological response, and will monitor for safety and tolerance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, National Jewish Health, Denver, CO 80206, USA; Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: nickj@njhealth.org.
- Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO 80045, USA.
- Department of Medicine, National Jewish Health, Denver, CO 80206, USA. Electronic address: lovellv@njhealth.org.
- Center for Genes, Environment, and Health, National Jewish Health, Denver, CO 80206, USA.
- Department of Medicine, National Jewish Health, Denver, CO 80206, USA.
- Department of Medicine, National Jewish Health, Denver, CO 80206, USA; Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- Cystic Fibrosis Foundation
- Howard Hughes Medical Institute
Zitieren
APA
Nick, J. A., Martiniano, S. L., Lovell, V. K., Vestal, B., Poch, K., Caceres, S. M., Rysavy, N. M., de Moura, V. C., Gilick, J. J., Malcolm, K. C., Pacheco, J., Amin, A. G., Chatterjee, D., Daley, C. L., Kasperbauer, S., Gross, J. E., Armantrout, E., Cohen, K. A., Keck, A., …, & Investigators of the Cystic Fibrosis NTM Consortium (2025). Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.03.669
Vancouver
Nick JA, Martiniano SL, Lovell VK, Vestal B, Poch K, Caceres SM, et al. Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.03.669
BibTeX
@article{Nick2025,
author = {Nick, Jerry A and Martiniano, Stacey L and Lovell, Valerie K and Vestal, Brian and Poch, Katie and Caceres, Silvia M and Rysavy, Noel M and de Moura, Vinicius Calado and Gilick, Jennifer J and Malcolm, Kenneth C and Pacheco, Jessica and Amin, Anita G and Chatterjee, Delphi and Daley, Charles L and Kasperbauer, Shannon and Gross, Jane E and Armantrout, Emily and Cohen, Keira A and Keck, Allison and Vandalfsen, Jill M and Magaret, Amalia S and Midamba, Nikita and Chapdu, Claire and Gao, Antao and Hill, Jane E and Freeman, Krista G and Cristinziano, Madison and Guerrero, Carlos and Jacobs-Sera, Deborah and Lauer, Michael J and Viland, Maggie and Hatfull, Graham F and Investigators of the Cystic Fibrosis NTM Consortium, Investigators of the Cystic Fibrosis NTM Consortium},
title = {Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.03.669}
}
EUVIMED